Overview: FLT3 Mutation Quantitative Monitoring TestIntroduction: The FLT3 Mutation Quantitative Monitoring Test quantifies FLT3 gene mutations to monitor acute myeloid leukemia treatment, preventing relapse. Aligned with 2023 ASH guidelines, it uses PCR for high sensitivity, aiding in cancer screening. This test is critical for guiding treatment adjustments and improving outcomes in molecular pathology for AML patients.
Other Names: FLT3 Quant Assay, FLT3 Mutation Monitoring Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: FLT3 quantitative testing began in the 2010s with AML treatment monitoring. Advanced PCR techniques emerged in the 2020s, improving sensitivity.
Purpose: Monitors AML treatment response, guides therapy adjustments, and quantifies FLT3 mutations to prevent relapse.
Test Parameters: 1. FLT3 Gene Mutation (Quantitative)
Pretest Condition: No fasting required. Collect whole blood or bone marrow at any time. Report treatment history and symptoms like fatigue or bruising.
Specimen: 2-5 mL whole blood (EDTA) or 2-5 mL bone marrow (EDTA). Transport in a biohazard bag within 24 hours.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document AML treatment history, fatigue, bruising, or relapse. Include current medications, especially targeted therapies.
Consent: Written consent required, detailing the tests purpose, monitoring implications, and potential need for therapy adjustments.
Procedural Considerations: Uses quantitative PCR to measure FLT3 mutation levels. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Low DNA yield or contamination can affect results. Treatment effects may alter mutation levels.
Clinical Significance: High FLT3 mutation levels suggest treatment resistance or relapse, prompting therapy changes. Low levels indicate response to treatment.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation.
Additional Supporting Tests: Bone marrow biopsy, minimal residual disease (MRD) testing, or flow cytometry to monitor AML.
Test Limitations: Sensitivity depends on mutation burden. Results require clinical correlation.
References: ASH Leukemia Guidelines, 2023; Blood, Döhner H, 2022.
